Bevacizumab in the treatment of ovarian cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 10, 2007, Pages 1339-1345

  Han, Ernest S ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiangiogenesis; Bevacizumab; Ovarian cancer; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; AVSATIN; AXITINIB; BELINOSTAT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; ERLOTINIB; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ANGIOGENESIS; AREA UNDER THE CURVE; ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTICLE; BLOOD TOXICITY; BRAIN ISCHEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG FATALITY; DRUG TOLERABILITY; EPITHELIAL OVARY CANCER; FEMALE; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTE; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HEMATOLOGIC DISEASE; INTESTINE PERFORATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); OVARIECTOMY; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SALVAGE THERAPY; STATISTICS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INTESTINAL PERFORATION; MULTICENTER STUDIES; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; SALVAGE THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35848943469     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.10.1339     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thus MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194-3200(2003).
3. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: Clinical Gynecologic Oncology (7th Edition). DiSaia PJ, Creasman WT (Eds). Mosby, Inc. 313-367 (2007).
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248-1259 (2002).
5. Bookman MA; on behalf of GCIG. GOG182-ICON5:5-arm Phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. 2006 ASCO Annual Meeting Proceedings Part I 24(Suppl. 18), 5002 (2006).
6. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
7. Ozols RF, Bookman MA, Young RC, du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol. Oncol. 103, 1-6 (2006).
8. Folkman J. Angiogenesis. Annu. Rev. Med. 57, 1-18 (2006).
9. Hirota, K, Semenza GL Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59(1), 15-26 (2006).
10. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16(9), 4604-4613 (1996).
11. Paley PJ, Staskus, KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80, 98-106 (1997).
12. Shen GH, Ghazizadeh M, Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 83(2), 196-203 (2000).
13. Obemair A, Waisicky R, Kaider A et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett. 138, 175-182 (1999).
14. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147(1), 9-19 (1993).
15. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer 14, 815-823 (2004).
16. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101, 1364-1374 (2004).
17. Hefler LA, Zeillinger R, Grimm C et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol. 103, 512-517 (2006).
18. Cooper BC, Ritchie JM, Broghammer CLW et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8, 3193-3197 (2002).
19. Zebrowski BK, Liu, W, Ramirez K, Akaqi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6(4), 373-378 (1999).
20. Sivarkumar B, Harry L, Paleolog EM. Modulating angiogenesis. JAMA 292, 972-977 (2004).
21. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
22. Emmanouilides C, Sfakiotaki G, Androulakis N et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter Phase II study. BMC Cancer 7, 91 (2007).
23. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
24. Miller K, Wang M, Gralow J et al. E2100: a randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer. Presented at: 41st Annual ASCO Meeting. Orlando, FL, USA, May 13-17, 2005.
25. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J. Clin. Oncol. 23(1), S2 (2005).
26. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-34 (2003).
27. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
28. Gerber HP, Ferrera N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671-680 (2005).
29. Kowanetz M and Napoleone F. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12(17), 5018-5022 (2006).
30. Dvorak, HF. Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312, 522-526 (2006).
31. Nummum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 102(3), 425-228 (2006).
32. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 96, 902-905 (2005).
33. Cohn DE, Valmadre S, Resnick KE et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102, 134-139 (2006).
34. Monk BJ, Han E, Josephs-Cowan CA et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102, 140-144 (2006).
35. Wright JD, Hagemann, A, Rader, JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer 107, 83-89 (2006).
36. Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol. 23(Suppl.), S457 (2005) (Abstract 5009).
37. Garcia AA, Oza AM, Hirte H et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium trial. J. Clin. Oncol. 23(Suppl.), S455 (2005) (Abstract 5000).
38. Cannistra SA, Matulonis, U, Penson R. et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol. Suppl. 24(Suppl. 18), (2006) (Abstract 5006).
39. Aghajanian C. The role of bevacizumab in ovarian cancer - an evolving story. Gynecol. Oncol. 102, 131-133 (2006).
40. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69(Suppl. 3), 25-33 (2005).
41. Friberg, G, Oza AM, Morgan RJ et al. Bevacizumab plus erlotinib for patients with recurrent ovarian and fallopian tube cancer: preliminary results of a multi-center Phase II trial. J. Clin Oncol. 24(Suppl. 18) (2006) (Abstract 5018).
42. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol. 105(1), 3-6 (2007).
43. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 6, 626-635 (2006).
44. Wright JD, Alvarezsecord A, Numnum TM et al. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. J. Clin Oncol. 24(Suppl. 18) (2006) (Abstract 5019).
45. Bidus MA, Webb JC, Seidman JD et al. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol. Oncol. 102, 5-7 (2006).
46. Penson RT, Cannistra SA, Seiden MV et al. Phase II study of carboplatin, paclitaxel. and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. J. Clin. Oncol. 24(Suppl. 18) (2006) (Abstract 5020).